SEI Investments’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $31.3M | Sell |
185,545
-49,706
| -21% | -$7.37M | 0.03% | 600 |
|
|
2026
Q1 | $31M | Buy |
235,251
+55,854
| +31% | +$7.41M | 0.03% | 608 |
|
|
2025
Q4 | $25.4M | Sell |
179,397
-120,798
| -40% | -$17.5M | 0.03% | 635 |
|
|
2025
Q3 | $42.1M | Buy |
300,195
+79,436
| +36% | +$10.8M | 0.05% | 429 |
|
|
2025
Q2 | $27.7M | Buy |
220,759
+79,334
| +56% | +$9.1M | 0.03% | 556 |
|
|
2025
Q1 | $15.6M | Sell |
141,425
-8,999
| -6% | -$1.14M | 0.02% | 785 |
|
|
2024
Q4 | $20.5M | Sell |
150,424
-4,695
| -3% | -$581K | 0.03% | 657 |
|
|
2024
Q3 | $17.9M | Buy |
155,119
+27,103
| +21% | +$3.72M | 0.02% | 724 |
|
|
2024
Q2 | $17.6M | Buy |
128,016
+41,347
| +48% | +$5.67M | 0.03% | 656 |
|
|
2024
Q1 | $12M | Sell |
86,669
-29,289
| -25% | -$4M | 0.02% | 833 |
|
|
2023
Q4 | $15.3M | Buy |
115,958
+25,416
| +28% | +$2.93M | 0.02% | 690 |
|
|
2023
Q3 | $10.2M | Sell |
90,542
-47
| -0.1% | -$4.95K | 0.02% | 850 |
|
|
2023
Q2 | $8.54M | Buy |
90,589
+6,417
| +8% | +$627K | 0.01% | 954 |
|
|
2023
Q1 | $8.52M | Sell |
84,172
-28,311
| -25% | -$2.95M | 0.02% | 937 |
|
|
2022
Q4 | $13.4M | Buy |
112,483
+2,270
| +2% | +$266K | 0.03% | 612 |
|
|
2022
Q3 | $11.7M | Buy |
110,213
+51,512
| +88% | +$5.23M | 0.03% | 695 |
|
|
2022
Q2 | $5.66M | Buy |
58,701
+1,879
| +3% | +$173K | 0.01% | 1031 |
|
|
2022
Q1 | $5.27M | Sell |
56,822
-3,647
| -6% | -$309K | 0.01% | 1081 |
|
|
2021
Q4 | $5.11M | Buy |
60,469
+2,695
| +5% | +$248K | 0.01% | 1129 |
|
|
2021
Q3 | $5.48M | Buy |
57,774
+88
| +0.2% | +$8.31K | 0.01% | 1031 |
|
|
2021
Q2 | $5.43M | Sell |
57,686
-2,569
| -4% | -$246K | 0.01% | 1033 |
|
|
2021
Q1 | $5.73M | Sell |
60,255
-25,788
| -30% | -$2.7M | 0.01% | 957 |
|
|
2020
Q4 | $8.13M | Buy |
86,043
+18,826
| +28% | +$1.82M | 0.02% | 739 |
|
|
2020
Q3 | $6.37M | Sell |
67,217
-5,856
| -8% | -$677K | 0.02% | 752 |
|
|
2020
Q2 | $8.72M | Buy |
73,073
+3,104
| +4% | +$343K | 0.03% | 603 |
|
|
2020
Q1 | $6.04M | Sell |
69,969
-6,055
| -8% | -$593K | 0.02% | 668 |
|
|
2019
Q4 | $8.17M | Sell |
76,024
-1,950
| -3% | -$204K | 0.02% | 670 |
|
|
2019
Q3 | $7.03M | Buy |
77,974
+7,864
| +11% | +$735K | 0.02% | 765 |
|
|
2019
Q2 | $5.92M | Buy |
70,110
+17,089
| +32% | +$1.4M | 0.02% | 854 |
|
|
2019
Q1 | $4.67M | Sell |
53,021
-58,204
| -52% | -$4.86M | 0.02% | 942 |
|
|
2018
Q4 | $13.4M | Buy |
111,225
+1,706
| +2% | +$163K | 0.05% | 423 |
|
|
2018
Q3 | $13.5M | Buy |
109,519
+4,541
| +4% | +$515K | 0.05% | 408 |
|
|
2018
Q2 | $10.3M | Sell |
104,978
-7,199
| -6% | -$644K | 0.04% | 567 |
|
|
2018
Q1 | $9.3M | Sell |
112,177
-21,127
| -16% | -$1.78M | 0.04% | 544 |
|
|
2017
Q4 | $10.3M | Buy |
133,304
+15,594
| +13% | +$1.06M | 0.04% | 598 |
|
|
2017
Q3 | $7.21M | Buy |
117,710
+11,321
| +11% | +$597K | 0.03% | 729 |
|
|
2017
Q2 | $4.89M | Buy |
106,389
+27,330
| +35% | +$1.33M | 0.02% | 853 |
|
|
2017
Q1 | $3.42M | Buy |
79,059
+9,363
| +13% | +$401K | 0.02% | 950 |
|
|
2016
Q4 | $2.7M | Buy |
69,696
+3,797
| +6% | +$172K | 0.01% | 1038 |
|
|
2016
Q3 | $3.34M | Buy |
65,899
+5,097
| +8% | +$254K | 0.02% | 879 |
|
|
2016
Q2 | $2.76M | Buy |
60,802
+50,358
| +482% | +$2.32M | 0.02% | 888 |
|
|
2016
Q1 | $413K | Sell |
10,444
-2,665
| -20% | -$106K | ﹤0.01% | 1354 |
|
|
2015
Q4 | $741K | Sell |
13,109
-30,252
| -70% | -$1.54M | ﹤0.01% | 1274 |
|
|
2015
Q3 | $1.73M | Buy |
43,361
+35,633
| +461% | +$1.72M | 0.02% | 850 |
|
|
2015
Q2 | $369K | Buy |
7,728
+6,344
| +458% | +$269K | ﹤0.01% | 1267 |
|
|
2015
Q1 | $55K | Buy |
+1,384
| New | +$49.5K | ﹤0.01% | 1667 |
|
Other funds holding NBIX
SEI Investments's NBIX Position: Q2 2026 in Review
SEI Investments reduced its Neurocrine Biosciences (NBIX) stake by 21% in Q2 2026, selling an estimated $7.37M and leaving 185,545 shares worth $31.3M. The position accounts for 0.03% of the portfolio, ranked #600.
SEI Investments first reported a position in NBIX in Q1 2015 and has held it in 46 quarters since. The position peaked at $42.1M in Q3 2025. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- SEI Investments held 185,545 shares of Neurocrine Biosciences worth $31.3M as of Q2 2026.
- SEI Investments sold 49,706 Neurocrine Biosciences shares in Q2 2026, an estimated $7.37M.
- Neurocrine Biosciences made up 0.03% of SEI Investments's portfolio in Q2 2026, its #600 holding.
- SEI Investments first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 46 quarters since.
- SEI Investments's Neurocrine Biosciences position peaked at $42.1M in Q3 2025.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.